# Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer

> **NCT06732531** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhuhai Beihai Biotech Co., Ltd** · enrollment: 48 (estimated)

## Conditions studied

- Bladder Cancer
- Non Muscle Invasive

## Interventions

- **DRUG:** BH011

## Key facts

- **NCT ID:** NCT06732531
- **Lead sponsor:** Zhuhai Beihai Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-08-03
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2025-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06732531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06732531, "Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06732531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*